Cover Image

Network Modeling of Biomarker Systems in Liver Steatosis and Fibrosis

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Amruta Gajanan Bhat, Murali Ramanathan
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Clinical and Translational Science
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Non‐neurological factors associated with serum neurofilament levels in the United States population
by: Murali Ramanathan
Published: (2024)

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor‐Mediated Drug‐Induced Liver Injury Using a Liver‐On‐Chip Model
by: Alan Shi, et al.
Published: (2025)

Pharmacokinetics as a Biomarker
by: John A. Wagner, et al.
Published: (2026)

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis
by: Ngoc Hoa Truong, et al.
Published: (2025)

Use of Biomarkers in Drug Development for Regulatory Purposes
by: Robert N. Schuck, et al.
Published: (2025)

Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline‐Induced Cardiotoxicity Using an Integrated PK / PD Model
by: Mohamed S. Dabour, et al.
Published: (2026)

A Long‐Term Human Liver Spheroid Model for Assessing Silencing and Durability of GalNAc ‐Conjugated siRNAs
by: Gijs‐Jan Scholten, et al.
Published: (2026)

Real‐World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study
by: Nicola Perrotta, et al.
Published: (2025)

Respiratory Biomarkers: An Opportunity for Patient‐Centric Microsampling Approach for Treatment Optimization
by: Ahmar Khan, et al.
Published: (2026)

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers
by: Bhagwat Prasad
Published: (2026)

Proteomic Identification of Plasma Biomarkers of Response to IL‐5 Inhibitor Biologics in Healthy Subjects
by: Lakshmi Manasa S. Chekka, et al.
Published: (2025)

Cancer Biomarker Test Utilization and Reimbursement in Australia: A National Analysis of Medicare Data
by: Leping Kong, et al.
Published: (2026)

Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study
by: Leila Potzel, et al.
Published: (2026)

The IQGAP1 ‐Claudin4‐ JNK Signaling Axis as a Differential Biomarker in Renal Cell Carcinoma
by: Nahshon Puente, et al.
Published: (2026)

Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC
by: Francis Williams Ojara, et al.
Published: (2026)

Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Diego Paine‐Cabrera, et al.
Published: (2025)

Glycoprotein Non‐Metastatic Melanoma Protein B ( GPNMB ): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition With VRG50635
by: Geraldine Gontier, et al.
Published: (2026)

Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics
by: Mai Mehanna, et al.
Published: (2025)

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment
by: Mohamed Hassanein, et al.
Published: (2026)

Linkage Between Hemoglobin to High Density Lipoprotein‐Cholesterol Ratio and Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationally Representative Study
by: Zhiping Liu, et al.
Published: (2025)

Recipient Versus Donor CYP3A4/5 Genotypes in Adult Liver Transplant Recipients to Achieve Therapeutic Tacrolimus Concentrations Early Post‐Transplant
by: Eda Eken, et al.
Published: (2025)

Mechanistic Evaluation of Anti‐CD19 CAR‐T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model
by: Hyunseo Park, et al.
Published: (2025)

Clinical Research Network: JHCRN Infrastructure and Lessons Learned
by: Rahul Kashyap, et al.
Published: (2025)

Clinician Satisfaction With Pharmacogenomics Clinical Services at a Multistate Health System
by: Kristen Jacobsen, et al.
Published: (2026)

Collaboration as a Catalyst for Advancing Rare Disease Research: The Experience of the Rare Diseases Clinical Research Network
by: Mirna Chehade, et al.
Published: (2026)

Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer
by: Li Chen, et al.
Published: (2025)

Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model
by: Seongmee Jeong, et al.
Published: (2025)

From Models to Medicines: A Narrative History and Regulatory Perspective on the Translational Impact of Model‐Informed Drug Development ( MIDD )
by: Issam Zineh
Published: (2026)

Can Environmental Enrichment Mitigate Cell Apoptosis in the Central Nervous System Under Adverse Health Conditions? A Systematic Review
by: Matheus Santos de Sousa Fernandes, et al.
Published: (2026)

Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment
by: David Rodrigues, et al.
Published: (2025)

Causal Effects of Renin–Angiotensin–Aldosterone System Inhibition on Renal Function in Patients With Chronic Kidney Disease: A Quasi‐Experimental Study
by: Tae Ryom Oh, et al.
Published: (2026)

Pharmacokinetic‐Pharmacodynamic Model of Paclitaxel‐Induced Peripheral Neuropathy
by: Yuchen Sun, et al.
Published: (2025)

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
by: Shota Yanagida, et al.
Published: (2025)

A Modeling Investigation of the CYP1A Drug Interactions of Riluzole
by: Paul Malik, et al.
Published: (2025)

Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome
by: Kevin Lam, et al.
Published: (2025)

Optimizing Oligonucleotide Therapeutics: A Model‐Informed Drug Development Perspective
by: Ye Yuan, et al.
Published: (2026)

Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach
by: Ahsan Rizwan, et al.
Published: (2025)

Bench to Bedside Modeling of mRNA Encoding IgG Using a Multiscale Mechanistic Pharmacokinetic‐Toxicokinetic ( PK ‐ TK ) Model: A Case Study With Anti‐Claudin 18.2
by: Devam A. Desai, et al.
Published: (2025)

Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20
by: Ryan P. Nolan, et al.
Published: (2024)

Translatability of Animal Models for Alzheimer's Disease Using a Machine Learning Based Workflow
by: Alex Foster‐Powell, et al.
Published: (2025)